Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 2221106 approvals4 trials

Pangen Biotech Inc.

Official website

Founded in 2010 and KOSDAQ-listed in 2016, Pangen Biotech develops an EPO biosimilar and provides biopharmaceutical CDMO services.

As of 2026-10-07, Pangen Biotech Inc. has 6 Korean MFDS drug approvals, 6 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2010 and listed on KOSDAQ in 2016, Pangen Biotech is a biosimilar and biopharmaceutical CDMO company. Using its PanGen CHO-TECH™ technology, it sells an EPO biosimilar for anemia in chronic renal failure patients under the brand names Panpotin (Korea, Saudi Arabia, Thailand) and Erysaa (Malaysia, Philippines), and provides biopharmaceutical contract manufacturing (CMO) and development/technology transfer (CDO) services. The EPO biosimilar received marketing approvals in Malaysia (2019), Korea (2019), the Philippines (2022), Saudi Arabia (2023), and Thailand (2024), reaching five countries, and the company is also developing Factor VIII for hemophilia A, Aflibercept for macular degeneration and macular edema, an anti-SFTSV antibody, and G-CSF as a cancer treatment adjuvant.

Products & technology

  • EPO biosimilar (Panpotin/Erysaa)Anemia treatment for chronic renal failure patients
  • CDMO/CDO serviceContract development and manufacturing, and technology transfer for biopharmaceuticals including preclinical/clinical samples

Regulatory approvals

data.go.kr

6 Korean MFDS drug approvals · 2018–2023

  • MFDS drugPanpotin Prefilled Syringe 10000 IU (Epoetin alfa)2023-08-25
    Drug · Prescription · Approval202302526
  • MFDS drugPanpotin Prefilled Syringe 6000 IU (Epoetin alfa)2023-08-25
    Drug · Prescription · Approval202302527
  • MFDS drugPANPOTIN2019-11-28
    Drug · Prescription · Approval201908142
  • MFDS drugPANPOTIN2019-11-28
    Drug · Prescription · Approval201908143
  • MFDS drugERYSAA2018-04-04
    Drug · Prescription · Approval201801487
  • MFDS drugERYSAA2018-04-04
    Drug · Prescription · Approval201801488

Clinical trials

data.go.kr

4 MFDS clinical trial authorisations · 2012–2021 (Phase 3 2 · Phase 1 2)

  • Phase 3PGA40 주 250 IU, 500 IU, 1000 IU2021-09-17

    1 trial site

  • Phase 1PGA40 주 250 IU, 500 IU, 1000 IU2019-03-25

    2 trial sites

  • Phase 3PDA10 프리필드주 2000 IU2012-12-21

    5 trial sites

  • Phase 1PDA10 프리필드주 2000 IU2012-06-08

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

Factor VIII · 혈우병A · Hemophilia A treatment

Aflibercept · 황반변성, 황반부종 · Treatment for macular degeneration and macular edema

항SFTSV항체 · 중증열성혈소판감소증후군(SFTS) · Treatment for severe fever with thrombocytopenia syndrome

G-CSF · 항암치료보조 · Cancer treatment adjuvant

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 17 more patents

AI reads

MAA server logs · IP-verified
16
Times AI engines pulled Pangen Biotech Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

2
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

14
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

4
live 1
Last 7 days
10
live 2
Last 30 days
16
live 2
All time
  • OpenAIChatGPT-Userlive2
  • OpenAIOAI-SearchBot8
  • GoogleGoogleOther2
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 5, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Pangen Biotech Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition